Takara Bio Inc
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for… Read more
Takara Bio Inc (TF2) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2024: 0.011x
Based on the latest financial reports, Takara Bio Inc (TF2) has a cash flow conversion efficiency ratio of 0.011x as of March 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.23 Billion) by net assets (€111.78 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Takara Bio Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Takara Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Takara Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Takara Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Primis Financial Corp
NASDAQ:FRST
|
-0.027x |
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
0.023x |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
N/A |
|
Tianjin Jiuri New Materials Co Ltd
SHG:688199
|
0.022x |
|
APG SGA SA
SW:APGN
|
0.000x |
|
Hunan Resun Co Ltd
SHE:001218
|
0.053x |
|
ASRock Inc
TW:3515
|
-0.040x |
|
Jiangsu Holly Corp
SHG:600128
|
0.038x |
Annual Cash Flow Conversion Efficiency for Takara Bio Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Takara Bio Inc from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €115.85 Billion | €5.84 Billion | 0.050x | +229.57% |
| 2024-03-31 | €111.78 Billion | €1.71 Billion | 0.015x | -95.33% |
| 2023-03-31 | €112.45 Billion | €36.90 Billion | 0.328x | +351.24% |
| 2022-03-31 | €96.06 Billion | €6.99 Billion | 0.073x | -61.25% |
| 2021-03-31 | €74.30 Billion | €13.94 Billion | 0.188x | +97.13% |
| 2020-03-31 | €66.59 Billion | €6.34 Billion | 0.095x | +5.51% |
| 2019-03-31 | €64.09 Billion | €5.78 Billion | 0.090x | +42.07% |
| 2018-03-31 | €61.96 Billion | €3.94 Billion | 0.064x | +6.30% |
| 2017-03-31 | €59.98 Billion | €3.58 Billion | 0.060x | +18.88% |
| 2016-03-31 | €60.11 Billion | €3.02 Billion | 0.050x | -15.75% |
| 2015-03-31 | €59.64 Billion | €3.56 Billion | 0.060x | +51.40% |
| 2014-03-31 | €57.13 Billion | €2.25 Billion | 0.039x | -- |